Abstract
Parkinson’s disease (PD) is the second most common neurodegenerative disorder whose prevalence is rapidly increasing worldwide. The disease mechanisms of sporadic PD are not yet completely understood. Therefore, causative therapies are still lacking. To obtain a more integrative view of disease-mediated alterations, we investigated the molecular landscape of PD in human post-mortem midbrains. Tissue from 13 PD patients and 10 controls was subjected to small RNA sequencing, transcriptomics, and proteomics analysis. Differential expression analyses were performed reveal multiple deregulated molecular targets linked to known pathomechanisms of PD as well as novel processes. We found significant differential expression of miR-539-3p, miR-376a-5p, miR-218-5p, and miR-369-3p, the valid miRNA-mRNA interacting pairs of miR-218-5p/RAB6C, and miR-369-3p/GTF2H3, as well as multiple proteins relevant in the pathology of PD, including CHI3L1, SELENBP1, PRDX1, HSPA1B, and TH. Vertical integration of multiple omics analyses allowed to validate disease-mediated molecular alterations across different molecular layers and functional annotation of differentially expressed targets identified a strong enrichment of pathways related to inflammation and activation of the immune response. This suggests that neuroinflammation may significantly contribute to disease progression in PD and may be a promising therapeutic target in advanced stages of PD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Cluster of Excellence and DFG Research Center Nanoscale Microscopy and Molecular Physiology of the Brain, Goettingen, Germany (PL), and by Bridging Funds from the Goettingen Graduate Center for Neurosciences, Biophysics, and Molecular Biosciences (LCG).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All human midbrain samples were provided by the Parkinson's UK Brain Bank (Imperial College London, London, England). The samples were conceded to the Lingor Lab (Department of Neurology, University Medical Center Goettingen, Goettingen, Germany). Ethical approval was given by the Multicenter Research Ethics Committee (07/MRE09/72).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing Interest Statement: The authors declare no conflict of interest for this study.
Data Availability
RNA sequencing and proteomics datasets were deposited in public repositories (the European Genome-phenome Archive (EGA) and the Proteomics Identifications Database (PRIDE), respectively) following applicable guidelines. RNA sequencing data are stored under the accession number EGAD00001006883. Proteomics data are available via ProteomeXchange with the identifier PXD023618.
Figure legends – Abbreviations
- CTR
- control
- PD
- Parkinson’s disease
- PMI
- postmortem interval
- Age
- age at death
- NP diagnosis
- neuropathological diagnosis
- Gender
- F-females/M-males
- LBDBS
- Lewy body disease brainstem variant
- LBDE
- Lewy body disease early-neocortical stage
- LBDN
- Lewy body disease neocortical stage
- miRNA
- microRNA
- GO
- Gene Ontology
- BP
- biological process
- CC
- cellular compartment
- KEGG
- Kyoto Encyclopedia of Genes and Genomes
- FDR
- false discovery rate
- DE
- differentially expressed
- FC
- fold change
- piRNA
- Piwi-interacting RNA
- rRNA
- ribosomal RNA
- snoRNA
- small nucleolar RNA
- sncRNA
- small non-coding RNA
